

Supplementary Appendix

This appendix has been provided by the authors to show revised versions of Tables 1–5.

Supplement to: Ballard RA. Inhaled nitric oxide in preterm infants — correction. *N Engl J Med* 2007;357:1444-5.

Table 1: Row 1, Column 4, previous value was 0.45 and has been changed to 0.53
 Row 2, Column 4, previous value was 0.60 and has been changed to 0.79
 Row 4, Column 4, previous value was 0.38 and has been changed to 0.45
 Row 5, Column 4, previous value was 0.37 and has been changed to 0.46
 Row 6, Column 4, previous value was 0.22 and has been changed to 0.25
 Row 11, Column 4, previous value was 0.23 and has been changed to 0.27
 Row 12, Column 4, previous value was 0.25 and has been changed to 0.32
 Row 13, Column 4, previous value was 0.58 and has been changed to 0.64
 Row 15, Column 4, previous value was 0.68 and has been changed to 0.77
 Row 16, Column 4, previous value was 0.71 and has been changed to 0.75
 Row 17, Column 4, previous value was 0.60 and has been changed to 0.62
 Row 22, Column 4, previous value was 0.76 and has been changed to 0.91
 Row 23, Column 4, previous value was 0.84 and has been changed to 0.92
 Row 24, Column 4, previous value was 0.83 and has been changed to 1.00
 Row 25, Column 4, previous value was 0.36 and has been changed to 0.38
 Row 26, Column 4, previous value was 0.13 and has been changed to 0.17

Table 1. Baseline Characteristics of the Infants *

Characteristics	Inhaled Nitric Oxide (N=294)	Placebo (N=288)	P value
Birth Weight			
Mean - g	766±161	759±155	0.53
500-799 – no. (%)	197(67.0)	197(68.4)	0.79
800-1250 – no. (%)	97(33.0)	91(31.6)	
Gestational Age – wk	26±1.5	26±1.5	0.45
Male Sex – no. (%)	155(52.7)	162(56.2)	0.46
Mother's race or ethnic group [†] – no. (%)			0.25
White	170(57.8)	145(50.3)	
Black	76(25.9)	90(31.3)	
Hispanic	32(10.9)	43(14.9)	
Other	16(5.4)	10(3.5)	
Antenatal corticosteroids – no. (%)	243(82.7)	229(79.5)	0.27
Surfactant – no. (%)	288(98.0)	277(96.2)	0.32
Vitamin A – no. (%)	154(52.4)	160(55.6)	0.64
Age at entry			
Median (interquartile range) - days	16(12, 19)	16(13, 19)	0.77
Age 7-14 days at entry – no. (%)	112(38.1)	115(39.9)	0.75
Respiratory severity score at entry [‡]			
<3.5 – no. (%)	162(55.1)	149(51.7)	0.62

Characteristics	Inhaled Nitric Oxide (N=294)	Placebo (N=288)	P value
3.5 – <10 – no. (%)	120(40.8)	126(43.8)	
≥10 – no. (%)	12(4.1)	13(4.5)	
Clinical complications – no. (%)			
Pneumothorax or Pneumomediastinum	34(11.6)	32(11.1)	0.91
Patent ductus arteriosus – no. (%)	192(65.3)	194(67.4)	0.92
Necrotizing enterocolitis – no. (%)	12(4.1)	11(3.8)	1.00
Sepsis – no. (%)	70(23.8)	58(20.1)	0.38
Grade 3 or 4 intraventricular hemorrhage – no. (%)	35(11.9)	45(15.6)	0.17
Type of ventilation			0.66
Conventional – no. (%)	202(68.7)	191(66.3)	
High Frequency – no. (%)	65(22.1)	74(25.7)	
Nasal CPAP – no. (%)	27(9.2)	23(8.0)	

Table 2: Row 1, Column 4, previous value was 0.04 and has been changed to 0.03
 Row 1, Column 5, previous value was 1.23 (1.01-1.51) and has been changed to 1.26 (1.02-1.55)
 Row 2, Column 3, previous value was 106/288 (36.8) and has been changed to 105/288 (36.5)
 Row 3, Column 3, previous value was 182/288 (63.2) and has been changed to 183/288 (63.5)
 Row 4, Column 3, previous value was 164/288 (56.9) and has been changed to 165/288 (57.3)
 Row 6, Column 4, previous value was 0.14 and has been changed to 0.07
 Row 6, Column 5, previous value was 1.20 (0.94-1.54) and has been changed to 1.26 (0.98-1.62)
 Row 7, Column 3, previous value was 74/197 (37.6) and has been changed to 73/197 (37.1)
 Row 8, Column 3, previous value was 123/197 (62.4) and has been changed to 124/197 (62.9)
 Row 9, Column 3, previous value was 108/197 (54.8) and has been changed to 109/197 (55.3)
 Row 10, Column 5, previous value was 1.01 (0.96-1.07) and has been changed to 1.02 (0.96-1.08)
 Row 11, Column 4, previous value was 0.14 and has been changed to 0.21
 Row 11, Column 5, previous value was 1.30 (0.91-1.87) and has been changed to 1.25 (0.88-1.79)

Table 2. Incidence of Primary Outcome

Outcome	Inhaled Nitric Oxide	Placebo	P Value	Relative Benefit (95% CI)
Overall population				
Survival without chronic lung disease	129/294(43.9)	105/288(36.5)	0.03	1.26(1.02- 1.55)
Death or survival with chronic lung disease	165/294(56.1)	183/288(63.5)		
Chronic lung disease	149/294(50.7)	165/288(57.3)		
Death	16/294(5.4)	18/288(6.3)		
Birth weight of 500-799 g				
Survival without chronic lung disease	85/197(43.1)	73/197(37.1)	0.07	1.26(0.98- 1.62)
Death or survival with chronic lung disease	112/197(56.9)	124/197(62.9)		
Chronic lung disease	99/197(50.3)	109/197(55.3)		
Death	13/197(6.6)	15/197(7.6)		1.02(0.96- 1.08)
Birth weight of 800-1250 g				
Survival without chronic lung disease	44/ 97(45.4)	32/ 91(35.2)	0.21	1.25(0.88- 1.79)
Death or survival with chronic lung disease	53/ 97(54.6)	59/ 91(64.8)		
Chronic lung disease	50/ 97(51.5)	56/ 91(61.5)		
Death	3/ 97(3.1)	3/ 91(3.3)		1.00(0.95- 1.06)

Table 3: Row 1, Column 8, previous value was 0.01 and has been changed to 0.008

Table 3. Outcome According to the Severity of Disease at 40 and 44 Weeks of Postmenstrual Age

	500-799 g		800-1250 g		All Infants		P value
	Nitric Oxide (N=197)	Placebo (N=197)	Nitric Oxide (N=97)	Placebo (N=91)	Nitric Oxide (N=294)	Placebo (N=288)	
Severity of Disease at 40 wk							0.01
Discharged	82(41.6)	60(30.5)	43(44.3)	38(41.8)	125(42.5)	98(34.0)	
Hospitalization without support	45(22.8)	44(22.3)	21(21.6)	12(13.2)	66(22.4)	56(19.4)	
Hospitalization with oxygen only	40(20.3)	55(27.9)	26(26.8)	29(31.9)	66(22.4)	84(29.2)	
Hospitalization with mechanical ventilation	15(7.6)	21(10.7)	3(3.1)	9(9.9)	18(6.1)	30(10.4)	
Death	15(7.6)	16(8.1)	4(4.1)	3(3.3)	19(6.5)	19(6.6)	0.03
Unknown	0	1(0.5)	0	0	0	1(0.3)	
Severity of Disease at 44 wk							
Discharged	151(76.6)	129(65.5)	82(84.5)	70(76.9)	233(79.3)	199(69.1)	
Hospitalization without support	6(3.0)	15(7.6)	2(2.1)	4(4.4)	8(2.7)	19(6.6)	
Hospitalization with oxygen only	19(9.6)	26(13.2)	8(8.2)	9(9.9)	27(9.2)	35(12.2)	
Hospitalization with mechanical ventilation	5(2.5)	8(4.1)	1(1.0)	4(4.4)	6(2.0)	12(4.2)	
Death	16(8.1)	16(8.1)	4(4.1)	4(4.4)	20(6.8)	20(6.9)	
Unknown	0	3(1.5)	0	0	0	3(1.0)	

Table 4: Row 1, Column 5, previous value was 0.91 and has been changed to 0.94
 Row 2, Column 5, previous value was 0.63 and has been changed to 0.65
 Row 3, Column 5, previous value was 0.84 and has been changed to 0.85
 Row 4, Column 5, previous value was 0.85 and has been changed to 0.90
 Row 5, Column 5, previous value was 1.00 and has been changed to 0.95
 Row 6, Column 5, previous value was 0.95 and has been changed to 0.92
 Row 7, Column 5, previous value was 0.67 and has been changed to 0.57

Table 4. Incidence of Clinical Complications after Study Entry

	Inhaled Nitric Oxide (N=294)	Placebo (N=288)	Relative Risk (95% CI)	P Value
Sepsis	121(41.2)	118(41.0)	0.99(0.81,1.22)	0.94
Necrotizing enterocolitis	23(7.8)	19(6.6)	1.16(0.64,2.11)	0.65
Necrotizing enterocolitis with surgery	10(3.4)	8(2.8)	1.19(0.46,3.11)	0.85
Patent ductus arteriosus treated	54(18.4)	55(19.1)	0.96(0.68,1.37)	0.90
Retinopathy of prematurity	246(83.7)	236(81.9)	1.00(0.93,1.07)	0.95
Retinopathy of prematurity with surgery	72(24.5)	68(23.6)	0.99(0.73,1.34)	0.92
Neurological evolution*	13(5.1)	10(4.1)	1.29(0.56,2.99)	0.57

Table 5: Row 1, Column 5, previous value was 0.006 and has been changed to 0.005
 Row 2, Column 4, previous value was 1.81 (1.27-2.59) and has been changed to 1.91 (1.31-2.78)
 Row 3, Column 3, previous value was 32/115 (27.8) and has been changed to 31/115 (27.0)
 Row 8, Column 5, previous value was 0.20 and has been changed to 0.32
 Row 9, Column 4, previous value was 1.26 (1.00-1.58) and has been changed to 1.28 (1.02-1.61)
 Row 10, Column 3, previous value was 69/149 (46.3) and has been changed to 68/149 (45.6)
 Row 12, Column 4, previous value was 1.10 (0.74-1.64) and has been changed to 1.11 (0.74-1.66)
 Row 15, Column 5, previous value was 0.05 and has been changed to 0.06
 Row 17, Column 4, previous value was 1.04 (0.76-1.43) and has been changed to 1.06 (0.76-1.47)
 Row 18, Column 3, previous value was 32/90 (35.6) and has been changed to 31/90 (34.4)
 Row 18, Column 4, previous value was 1.66 (1.16-2.37) and has been changed to 1.72 (1.20-2.47)
 Row 19, Column 4, previous value was 1.62 (1.04-2.53) and has been changed to 1.66 (1.06-2.59)
 Row 20, Column 4, previous value was 0.57 (0.27-1.20) and has been changed to 0.54 (0.25-1.14)
 Row 22, Column 4, previous value was 1.37 (0.81-2.32) and has been changed to 1.50 (0.85-2.65)
 Row 23, Column 3, previous value was 16/63 (25.4) and has been changed to 15/63 (23.8)
 Row 23, Column 4, previous value was 2.32 (1.43-3.77) and has been changed to 2.50 (1.53-4.11)
 Row 29, Column 3, previous value was 41/82 (50.0) and has been changed to 40/82 (48.8)
 Row 29, Column 4, previous value was 1.37 (1.05-1.80) and has been changed to 1.38 (1.06-1.81)
 Row 31, Column 4, previous value was 0.88 (0.52-1.50) and has been changed to 0.92 (0.54-1.57)
 Row 32, Column 4, previous value was 1.52 (0.84-2.76) and has been changed to 1.49 (0.81-2.67)

Table 5. Post Hoc Subgroup Analysis of Survival without Chronic Lung Disease at 36 Weeks of Postmenstrual Age

	Inhaled Nitric Oxide (N=294)	Placebo (N=288)	Relative Benefit (95% CI)	P Value
Age at Entry				0.005
7-14 days			1.91(1.31- 2.78)	
Survival without chronic lung disease	55/112(49.1)	31/115(27.0)		
Death	12/112(10.7)	13/115(11.3)		
15-21 days			0.99(0.77- 1.28)	
Survival without chronic lung disease	74/182(40.7)	74/173(42.8)		
Death	12/182(6.6)	10/173(5.8)		
Severity score at entry				0.32
<3.5			1.28(1.02- 1.61)	
Survival without chronic lung disease	92/162(56.8)	68/149(45.6)		
Death	9/162(5.6)	9/149(6.0)		
≥3.5			1.11(0.74- 1.66)	
Survival without chronic lung disease	37/132(28.0)	37/139(26.6)		
Death	15/132(11.4)	14/139(10.1)		
Survival without chronic lung disease				0.06
Race or ethnic group				
White	59/170(34.7)	50/145(34.5)	1.06(0.76- 1.47)	
Black	43/ 76(56.6)	31/ 90(34.4)	1.72(1.20- 2.47)	
Hispanic	21/ 32(65.6)	17/ 43(39.5)	1.66(1.06- 2.59)	
Other	6/ 16(37.5)	7/ 10(70.0)	0.54(0.25, 1.14)	

	Inhaled Nitric Oxide (N=294)	Placebo (N=288)	Relative Benefit (95% CI)	P Value
Age at Entry				0.005
7-14 days			1.91(1.31- 2.78)	
Age of 7-14 days at entry				
White	24/ 60(40.0)	16/ 52(30.8)	1.50(0.85- 2.65)	
Non-White	31/ 52(59.6)	15/ 63(23.8)	2.50(1.53- 4.11)	
Age of 15-21 days at entry				
White	35/110(31.8)	34/ 93(36.6)	0.89(0.60- 1.34)	
Non-White	39/ 72(54.2)	40/ 80(50.0)	1.13(0.83- 1.55)	
Severity score <3.5 at entry				
White	38/ 82(46.3)	28/ 67(41.8)	1.14(0.78- 1.66)	
Non-White	54/ 80(67.5)	40/ 82(48.8)	1.38(1.06- 1.81)	
Severity score ≥3.5 at entry				
White	21/ 88(23.9)	22/ 78(28.2)	0.92(0.54- 1.57)	
Non-White	16/ 44(36.4)	15/ 61(24.6)	1.47(0.81- 2.67)	